Page last updated: 2024-11-04

temozolomide and Hypogonadism

temozolomide has been researched along with Hypogonadism in 2 studies

Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).

Research Excerpts

ExcerptRelevanceReference
"Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients."5.05Prolactinomas in males: any differences? ( Duskin-Bitan, H; Shimon, I, 2020)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Wildemberg, LE1
Fialho, C1
Gadelha, MR1
Duskin-Bitan, H1
Shimon, I1

Reviews

2 reviews available for temozolomide and Hypogonadism

ArticleYear
Prolactinomas.
    Presse medicale (Paris, France : 1983), 2021, Volume: 50, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon

2021
Prolactinomas in males: any differences?
    Pituitary, 2020, Volume: 23, Issue:1

    Topics: Cabergoline; Dopamine Agonists; Humans; Hypogonadism; Male; Pituitary Neoplasms; Prolactinoma; Somat

2020